Congress’s 2026 hemp extension and a new executive order are reshaping the cannabinoid market, forcing companies to separate intoxicating THC from non‑intoxicating cannabinoids. Industry leaders warn that the 0.4 mg THC cap and a fragmented state regulatory patchwork create urgent compliance challenges.
Two Industry Vantage Points
FloraWorks produces TruCBN, a purified, non‑intoxicating CBN derived from hemp. CEO Lindquist says the 0.4 mg THC cap is immaterial to its purified‑ingredient business.
Lindquist notes that the cap will affect broader hemp brands and that the company is filing a New Dietary Ingredient Notification with the FDA, with submission slated for later this year. He emphasizes that the product remains fully compliant under current regulations.
Lindquist adds that its GLP toxicology data have been peer‑reviewed and its GRAS determination is under independent expert panel review, while the firm conducts an observational sleep study with TruCBN. The study aims to generate real‑world evidence for clinical use.
Managing a fragmented state regulatory landscape remains a core operational burden, as inconsistent testing, documentation, licensing and quality standards force companies to secure local licenses or partner with in‑state entities. Lindquist says this complexity drives the need for dedicated compliance resources.
The reimbursement pathway through CMS’s Substance Access Beneficiary Engagement Incentive makes TruCBN eligible in any state that permits hemp‑derived CBD or other non‑intoxicating cannabinoids, pending a state‑by‑state legal review.
What Are the Takeaways for Brands?
The evolving legislation and ambiguous deadlines leave brands navigating a stressful, uncertain environment with high compliance burdens. Brands must stay agile as definitions continue to evolve.
Miller of the US Hemp Roundtable says a hemp fix is likely by November, citing strong presidential support, and the industry remains resolved to fight for favorable policy. He says the outlook remains cautiously optimistic despite the pending regulatory timeline.
Lindquist warns that no immediate supply‑chain disruption is expected on November 12, and advises brands to monitor implementation, review product portfolios, and avoid unnecessary changes until guidance clarifies the new definitions.
